← Leaderboards
John Vincent Mulcahy
Siteone Therapeutics, Inc.
$6,301,912
Attributed
$11,847,502
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.3M · FY2013–23$10M$7.5M$5M$2.5M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$11,847,502 · 7
By mechanism
UG3$5,341,667 · 1
R44$4,617,019 · 2
U44$1,143,705 · 1
R43$745,111 · 3
Top collaborators
- Anton Delwig3 shared
- John Cureton Hunter3 shared
- George Miljanich3 shared
- Debra Odink3 shared
Most similar at Siteone Therapeutics, Inc.
Same institution · by research overlap
- Anton Delwig$2,325,019
- Debra Odink$3,260,885
- John Cureton Hunter$6,388,430
- George Miljanich$601,209
- Sheri Denet Klas$1,802,944
Others in their field
Top investigators on “Protein Isoforms”
- Randall J Bateman · Washington University$79,170,583
- Rolf Apweiler · European Molecular Biology Laboratory$41,336,566
- Stanley B Prusiner · University Of California San Francisco$33,187,893
- Howard Y Chang · Stanford University$26,252,541
- David A Bennett · Rush University Medical Center$25,855,566
- Yadong Huang · J. David Gladstone Institutes$24,532,318
Research focus
Protein IsoformsPharmaceutical PreparationsPre-ClinicalVoltageDoseExhibitsSafetyToxic EffectRodentRattusTransmission ProcessProgramsSodium ChannelPainLeadIon ChannelAcuteAnalgesicsInhibitor/AntagonistSignal TransductionSensoryIn VivoGeneticProteins
Grant awards (13)
Development of a Potent and Selective Nav1.8 inhibitor for the Treatment of Acute and Chronic Pain with the Goal of Reducing Opioid Use and Preventing Opioid Use Disorders$5,341,667
UG3 · FY2023 · DA
Development of Nav1.7 Selective Inhibitors for the Treatment of Chronic Cough$1,055,826
R44 · FY2022 · HL
Development of Nav1.7 Selective Inhibitors for the Treatment of Chronic Cough$677,568
R44 · FY2021 · HL
Discovery of NaV1.7 Inhibitors for the Treatment of Pain$455,622
U44 · FY2021 · NS · contact PI
Discovery of NaV1.7 Inhibitors for the Treatment of Pain$461,907
U44 · FY2020 · NS · contact PI
Discovery of NaV1.7 Inhibitors for the Treatment of Pain$226,176
U44 · FY2019 · NS · contact PI
Development of Selective Inhibitors of NaV1.7 as Therapeutics for Pain$829,314
R44 · FY2017 · NS · contact PI
Development of Selective Inhibitors of NaV1.7 as Therapeutics for Pain$616,855
R44 · FY2016 · NS · contact PI
Development of Selective Inhibitors of NaV1.7 as Therapeutics for Pain$756,321
R44 · FY2015 · NS · contact PI
Guanidinium Derivatives for the Treatment of Ocular Pain$223,828
R43 · FY2015 · EY
Development of Selective Inhibitors of NaV1.7 as Therapeutics for Pain$681,135
R44 · FY2014 · NS · contact PI
Evaluation of Sodium Channel Inhibitors as Therapeutics for Chronic Muscle Disord$285,048
R43 · FY2013 · GM · contact PI
Design, Synthesis and Evaluation of Novel Isoform-Selective Sodium Channel Inhibi$236,235
R43 · FY2013 · NS · contact PI